Johnson & Johnson is one of the largest healthcare and consumer product companies in the world, employing 136,500 people. Revenues of between $88-90 billion are expected for 2021. Its three divisions comprise Consumer, Pharmaceutical, and Medical Devices.
Wealth Builder
Sorry, you do not have access to this content.Income Investor
Sorry, you do not have access to this content.Having more than tripled since our original recommendation, and up 6% in the last year against a 14% fall in the S&P 500, JNJ remains a Buy for its strong balance sheet, steady high single-digit growth in earnings, and reasonable dividend. - Gavin Graham
Current Advice
Buy
Consult your broker/advisor
Capital Gain/Loss
175.0%